How Peptides Are Made — Synthesis to Purity | Real Peptides

How Peptides Are Made — Synthesis to Purity | Real Peptides

Research-grade peptide quality is determined long before it reaches your lab. It's set the moment synthesis begins. A contaminated batch doesn't happen during shipping or storage. It happens when amino acids are coupled incorrectly, when deprotection steps fail, or when purification is rushed. Understanding how peptides are made isn't optional for serious researchers. It's the baseline knowledge that separates reliable results from wasted protocols.

We've worked with hundreds of research teams across universities and private labs. The single most common issue isn't improper storage or reconstitution technique. It's purchasing peptides from suppliers who skip synthesis validation steps to cut costs. Real expertise in peptide synthesis means knowing where contamination enters the process and stopping it before the first lyophilisation cycle runs.

How are peptides made for research applications?

Peptides are made through solid-phase peptide synthesis (SPPS), a stepwise process where individual amino acids are sequentially coupled to a growing chain anchored to a resin. Each amino acid is protected to prevent unwanted reactions, deprotected after coupling, and the cycle repeats until the target sequence is complete. After synthesis, the peptide undergoes cleavage from the resin, purification via high-performance liquid chromatography (HPLC), and lyophilisation into powder form for stability during storage and shipping.

The difference between a peptide synthesised properly and one that isn't comes down to verification. Not just at the end, but at every coupling cycle. SPPS allows for unprecedented control over sequence accuracy, but only when each step is monitored. A single missed deprotection leaves a capping group attached, terminating the chain prematurely. A contaminated coupling reagent introduces deletion sequences. Shorter fragments that co-purify and dilute the target peptide's effective concentration. These aren't theoretical risks. They're the most common failure modes we see in third-party peptide batches that arrive for independent verification. This article covers the exact synthesis workflow used to produce research-grade peptides, the purification techniques that determine final purity, and the quality control checkpoints that separate reliable suppliers from those cutting corners.

The Solid-Phase Synthesis Process

Solid-phase peptide synthesis (SPPS) is the industry-standard method for producing research peptides because it allows complete automation of repetitive coupling cycles while maintaining sequence fidelity. The process begins with a solid resin bead. Typically polystyrene cross-linked with divinylbenzene. Functionalised with a linker that anchors the first amino acid. The resin remains stationary throughout synthesis while reagents are added and washed away in cycles, enabling high-throughput production without manual handling of intermediates.

Each synthesis cycle follows an identical pattern: deprotection, coupling, and capping. Deprotection removes the temporary N-terminal protecting group. Most commonly fluorenylmethyloxycarbonyl (Fmoc). Using a base such as piperidine in dimethylformamide (DMF). This exposes the terminal amine for the next coupling reaction. Coupling introduces the next protected amino acid along with activating reagents like HBTU (O-benzotriazole-N,N,N',N'-tetramethyl-uronium-hexafluoro-phosphate) or DIC (diisopropylcarbodiimide), which form the peptide bond between the incoming residue and the growing chain. Capping uses acetic anhydride to block any unreacted chains, preventing deletion sequences from forming in subsequent cycles.

The beauty of SPPS is its scalability and precision. But both depend entirely on reagent purity and timing control. A deprotection step that runs 30 seconds too short leaves partial Fmoc groups attached, creating truncated byproducts. Activating reagents that have degraded due to improper storage produce lower coupling efficiency, introducing failure sequences that are difficult to separate later. At Real Peptides, every batch undergoes real-time monitoring during synthesis using UV spectrophotometry to measure Fmoc release. Confirming complete deprotection before the next amino acid is added. This isn't standard practice across the industry. Many suppliers run synthesis on autopilot without mid-cycle verification, discovering sequence errors only after purification. When the peptide is already packaged and difficult to recall.

Once the full sequence is assembled, the peptide undergoes global deprotection and cleavage from the resin. Trifluoroacetic acid (TFA) cleaves the peptide-resin bond and removes side-chain protecting groups in a single step, releasing the crude peptide into solution. This mixture contains the target sequence along with truncated fragments, deletion sequences, and residual protecting groups. Making purification the next critical checkpoint.

HPLC Purification and Analytical Verification

Crude peptide mixtures straight from synthesis contain far more than the target sequence. Truncated chains from incomplete coupling, deletion sequences from skipped residues, and modified byproducts from side reactions all co-exist in the cleavage mixture. High-performance liquid chromatography (HPLC) separates these components based on hydrophobicity, allowing isolation of the correct full-length peptide at the purity level required for research applications.

Reversed-phase HPLC (RP-HPLC) is the standard purification method for peptides. The crude mixture is injected onto a column packed with hydrophobic stationary phase. Typically C18-bonded silica. And eluted using a gradient of water and acetonitrile, both acidified with 0.1% TFA. As the acetonitrile concentration increases, peptides elute in order of increasing hydrophobicity. The target peptide elutes as a distinct peak, which is collected, pooled, and lyophilised. Fractions containing truncated or modified sequences elute at different retention times and are discarded.

Purity is not a binary outcome. It's a spectrum, and the target matters. Research-grade peptides for biological assays typically require ≥95% purity by HPLC, while peptides for structural studies or in vivo work may require ≥98%. Lower-purity batches (85–90%) may appear acceptable on paper but contain 10–15% contaminating sequences that interfere with receptor binding, alter pharmacokinetics, or produce inconsistent dose-response curves. At Real Peptides, every production batch is purified to ≥98% purity and verified using both analytical HPLC and mass spectrometry (MS) before release. Analytical HPLC confirms purity by measuring peak area percentages. Mass spectrometry confirms identity by measuring the peptide's molecular weight to within 0.01% of the theoretical mass.

This dual-verification model catches errors that single-method testing misses. A peptide may show 97% purity by HPLC but contain a deletion sequence with nearly identical retention time. Only MS reveals the mass discrepancy. Conversely, MS confirms correct mass but cannot detect small-molecule contaminants like residual TFA or coupling reagents, which HPLC detects as separate peaks. We've tested third-party peptides that passed MS but failed HPLC purity thresholds due to salt contamination. A problem that becomes obvious only when researchers attempt reconstitution and find the peptide won't dissolve at expected concentrations. You can explore the full range of peptides synthesised under these standards at our peptide collection, where every product page includes the specific purity and mass spec data for that batch.

Lyophilisation, Storage Stability, and Reconstitution Chemistry

Once purified, peptides exist as aqueous solutions. A form that is chemically unstable over time due to hydrolysis, oxidation, and aggregation. Lyophilisation (freeze-drying) removes water under vacuum, converting the peptide into a stable powder that can be stored long-term without degradation. This process is not merely a convenience. It's a stability requirement for peptides with half-lives measured in hours when dissolved.

Lyophilisation begins by freezing the peptide solution to −40°C or below, converting water into ice crystals. The frozen sample is then placed under high vacuum, causing ice to sublimate directly from solid to vapor without passing through the liquid phase. A process called primary drying. Once all ice is removed, secondary drying raises the temperature slightly to remove residual bound water, yielding a dry powder with ≤1% moisture content. This powder remains stable at −20°C for 12–24 months, compared to aqueous peptides which degrade within days at the same temperature.

Reconstitution reverses this process, but the choice of solvent matters. Most research peptides dissolve readily in sterile water or bacteriostatic water. The latter containing 0.9% benzyl alcohol to prevent bacterial growth in multi-dose vials. Hydrophobic peptides may require the addition of a small volume of DMSO or acetic acid to facilitate dissolution, followed by dilution with aqueous buffer. The biggest mistake researchers make during reconstitution isn't contamination. It's injecting air into the vial while drawing solution. The resulting positive pressure forces contaminants back through the needle on every subsequent draw, introducing particulates that weren't present at the time of lyophilisation.

Storage conditions post-reconstitution are equally critical. Dissolved peptides should be aliquoted into single-use vials to avoid repeated freeze-thaw cycles, which cause aggregation and loss of bioactivity. Aliquots stored at −80°C remain stable for months; those kept at 4°C degrade within weeks depending on sequence. Peptides containing methionine, cysteine, or tryptophan are particularly prone to oxidation and should be handled under argon or nitrogen when possible. We've seen research protocols fail not because the peptide was impure, but because it was reconstituted once, frozen, thawed six times over three months, and had lost 40% of its activity before the first experiment even started. If your research depends on reproducibility, treat reconstituted peptides as perishable reagents. Because they are.

How Peptides Are Made: Synthesis Method Comparison

Different synthesis strategies produce peptides with varying purity, scalability, and cost profiles. The choice of method depends on peptide length, target purity, and production scale.

Solid-Phase Synthesis (SPPS)

95–99%

2–50 amino acids, mg to g scale

Research-grade peptides requiring high purity and custom sequences

Difficult for sequences >50 residues due to cumulative coupling errors

Gold standard for research peptides. Automation enables reproducibility and sequence verification at every step

Liquid-Phase Synthesis

85–95%

Economical for large-scale production (kg scale)

Industrial peptides where cost matters more than purity

Lower purity, more complex purification, limited to simpler sequences

Suitable for bulk production but lacks the precision required for biological assays

Recombinant Expression

Variable (often requires refolding)

Unlimited scale once expression system is optimised

Large therapeutic peptides and proteins (insulin, growth factors)

Requires molecular biology infrastructure, post-translational modifications may differ from native peptide

Only viable method for very long peptides or those requiring specific folding. Not cost-effective for short research peptides

Chemical Ligation (NCL)

90–98%

Used to combine shorter SPPS fragments into longer sequences

Peptides 50–200 residues where SPPS alone fails

Requires cysteine residues at ligation sites, complex optimisation

Niche application for difficult sequences. Most research peptides don't require this approach

SPPS dominates research peptide production because it offers the best combination of purity, sequence fidelity, and scalability for peptides in the 5–40 residue range. Which encompasses the vast majority of bioactive research compounds. Liquid-phase synthesis is cheaper per gram but introduces purification challenges that offset the cost savings unless production scale exceeds several kilograms. Recombinant expression makes sense for peptides like Thymalin or Cerebrolysin, where the peptide is part of a larger protein complex, but for shorter sequences like BPC-157 or Ipamorelin, SPPS is faster, cleaner, and more reliable.

Key Takeaways

Peptides are made through solid-phase synthesis (SPPS), where amino acids are coupled sequentially to a resin-bound chain, allowing automation and high sequence fidelity for peptides up to 50 residues.

Each synthesis cycle includes deprotection, coupling, and capping steps. Skipping verification at any stage introduces truncated or deletion sequences that co-purify and dilute effective peptide concentration.

HPLC purification separates the target peptide from synthesis byproducts based on hydrophobicity, with research-grade batches requiring ≥95% purity confirmed by both analytical HPLC and mass spectrometry.

Lyophilisation converts purified peptides into stable powder form by removing water under vacuum, extending shelf life from days (aqueous) to 12–24 months (lyophilised) when stored at −20°C.

Reconstitution errors. Particularly injecting air into vials during draws. Introduce contamination that wasn't present at synthesis, and repeated freeze-thaw cycles cause aggregation and bioactivity loss.

Real-time synthesis monitoring using UV spectrophotometry to measure Fmoc release at each cycle is not standard practice industry-wide, but it's the only way to catch coupling failures before purification.

What If: Peptide Synthesis Scenarios

What If the Peptide Sequence Contains Multiple Cysteine Residues?

Use orthogonal protecting groups (Acm, Trt) on cysteine side chains to control which cysteines form disulfide bonds during oxidative folding. Cysteines form disulfide bridges spontaneously in aqueous solution under oxidising conditions, and without selective protection, you'll get scrambled disulfides. Misfolded peptides with no biological activity. Controlled disulfide formation requires sequential deprotection: remove Trt groups first with mild acid, allow those cysteines to oxidise and form their intended bridge, then remove Acm groups with iodine to form the second bridge. This is why cyclic peptides and toxin-derived sequences often require custom synthesis protocols. One-size-fits-all SPPS doesn't handle complex disulfide topologies reliably.

What If the Peptide Precipitates During Synthesis?

Switch to a more polar resin or incorporate pseudoproline dipeptides at aggregation-prone positions to disrupt chain aggregation. Hydrophobic peptides aggregate on the resin during synthesis, forming β-sheet structures that prevent incoming amino acids from accessing the growing chain terminus. This causes coupling failures that don't show up until purification, when you discover your target peptide is a minor component in a mixture of truncated sequences. Pseudoprolines are temporary dipeptide replacements (serine-serine or threonine-threonine) that introduce kinks in the chain, preventing aggregation during synthesis. After cleavage, the pseudoproline reverts to the native sequence. You get the correct peptide without the aggregation problem.

What If Analytical HPLC Shows Multiple Peaks Close to the Target Retention Time?

Run the sample on a different HPLC column chemistry (phenyl-hexyl instead of C18) or use mass spectrometry to identify each peak. Close-eluting peaks often represent diastereomers (sequences with a single D-amino acid instead of L), deletion sequences missing one residue, or peptides with incomplete side-chain deprotection. C18 columns separate based on hydrophobicity, but switching to phenyl-hexyl or C4 columns changes selectivity and may resolve peaks that co-elute on C18. Mass spec identifies each peak by molecular weight. A deletion sequence will be 50–150 Da lighter than the target, while a diastereomer has identical mass but different retention time. If MS confirms the major peak is correct mass and the minor peaks are impurities, you're fine. If MS shows the target peak is a minor component, the batch failed synthesis and should be rejected.

The Unfiltered Truth About Peptide Synthesis Quality

Here's the honest answer: most peptide suppliers don't synthesise their own products. They outsource to contract manufacturers in Asia, rebrand the peptides, and sell them without independent verification. The purity listed on the certificate of analysis is copied from the manufacturer's report. Not tested in-house. When a batch fails, they don't know why, because they weren't there when it was made. They can't optimise synthesis conditions, troubleshoot coupling failures, or identify the specific step where contamination entered the process. They're resellers, not manufacturers.

The gap between a supplier who controls synthesis in-house and one who doesn't becomes obvious the moment a custom sequence is requested or a difficult peptide fails standard synthesis. In-house manufacturers adjust coupling times, switch protecting groups, or run test syntheses at analytical scale before committing to production. Resellers send the sequence to their contractor, wait three weeks, and hope it works. If it doesn't, they refund your order and move on. Because they have no technical capability to fix the problem.

At Real Peptides, synthesis happens in-house under direct oversight. Every batch is synthesised from individual amino acids using automated SPPS systems with real-time UV monitoring at each deprotection step. Crude peptides are purified using preparative HPLC, and every production lot undergoes dual verification with analytical HPLC and MALDI-TOF mass spectrometry before release. When a sequence requires optimisation. Aggregation-prone hydrophobic stretches, difficult cysteine pairings, or sequences prone to aspartimide formation. We run it at analytical scale first, identify the failure mode, adjust conditions, and re-run until the target purity is met. That capability doesn't exist at companies that outsource synthesis. It's the difference between selling peptides and understanding how peptides are made.

The way peptides are made determines everything that follows. Receptor affinity, bioavailability, reproducibility across experiments, and whether your research data is trustworthy or noise. A single misplaced amino acid in a GLP-1 analog like Tirzepatide or Retatrutide changes binding kinetics entirely. A 5% impurity in a growth hormone secretagogue like Ipamorelin or CJC-1295 means your dose-response curve is measuring two peptides, not one. Synthesis precision isn't a luxury. It's the baseline requirement for peptides that produce reliable, reproducible results. If your supplier can't explain how peptides are made in their own facility, with their own chemists, using their own quality control protocols. Find one who can.

Frequently Asked Questions

Peptides are synthesised using solid-phase peptide synthesis (SPPS), where amino acids are sequentially coupled to a resin-bound growing chain. Each cycle includes deprotection of the N-terminal protecting group (typically Fmoc), coupling of the next protected amino acid using activating reagents like HBTU or DIC, and capping of unreacted chains with acetic anhydride. After the full sequence is assembled, the peptide is cleaved from the resin using trifluoroacetic acid (TFA), purified via HPLC, and lyophilised into powder form for long-term storage.

SPPS builds peptides chemically by coupling individual amino acids in a controlled sequence, making it ideal for peptides up to 50 residues with high purity requirements (95–99%). Recombinant production expresses peptides inside genetically modified bacteria or yeast, which is scalable and cost-effective for large therapeutic proteins but introduces variability in folding and post-translational modifications. SPPS offers superior sequence fidelity and is the standard for research-grade peptides, while recombinant methods are reserved for very long sequences or proteins requiring specific cellular machinery.

No — visual inspection, solubility tests, and pH measurements cannot confirm peptide purity or identity. Only analytical HPLC (which separates components by retention time) and mass spectrometry (which confirms molecular weight) can detect truncated sequences, deletion byproducts, or residual protecting groups that co-exist in impure batches. Reputable suppliers provide certificates of analysis (CoA) with both HPLC chromatograms showing peak purity and MS data confirming the correct molecular mass. If a supplier cannot provide both, the peptide’s purity claim is unverified.

Research-grade peptides synthesised via SPPS and purified to ≥95% purity typically cost $2–$10 per milligram depending on sequence length, difficulty, and scale. Simple sequences under 15 residues are cheaper; sequences with multiple cysteines, hydrophobic stretches, or difficult coupling steps cost more due to lower yields and additional purification steps. Custom synthesis (non-catalog sequences) adds 20–40% to base cost due to method development and optimisation time. Bulk orders (grams instead of milligrams) reduce per-unit cost but require upfront synthesis optimisation.

Incomplete deprotection leaves Fmoc groups attached, terminating the chain prematurely and creating truncated byproducts. Inefficient coupling (due to degraded activating reagents or insufficient reaction time) produces deletion sequences missing one or more amino acids. Aspartimide formation occurs when aspartic acid residues cyclise with the backbone during synthesis, creating a mixture of correct and modified peptides. Aggregation of hydrophobic sequences on the resin prevents incoming amino acids from accessing the chain terminus, lowering coupling efficiency and increasing failure sequences.

SPPS offers higher purity (95–99%) and better sequence fidelity because each amino acid coupling occurs on a solid support, allowing unreacted reagents and byproducts to be washed away between steps. Liquid-phase synthesis keeps the growing peptide in solution, which is more economical for large-scale production but requires complex purification and typically yields 85–95% purity. For research applications requiring high purity and custom sequences under 50 residues, SPPS is the superior method. Liquid-phase synthesis is reserved for industrial-scale production where cost per kilogram outweighs purity precision.

Lyophilised peptides remain chemically stable at −20°C for 12–24 months, but sequences containing methionine, cysteine, or tryptophan are prone to oxidation even in powder form and should be stored under inert gas (argon or nitrogen) or in sealed ampoules to prevent air exposure. Peptides with free thiols (unpaired cysteines) can form disulfide-linked aggregates over time if exposed to moisture or oxygen. Hygroscopic peptides absorb atmospheric moisture, which accelerates hydrolysis and reduces shelf life — these should be stored in desiccated containers with silica gel packets.

Purity (measured by HPLC) reflects the percentage of the target peptide relative to all peptide-related impurities (truncated sequences, deletion products). Net peptide content accounts for non-peptide mass such as residual TFA salts, water, and counterions, which can constitute 10–30% of lyophilised powder weight. A peptide may be 98% pure by HPLC but only 70% net peptide content — meaning 30% of the vial’s mass is not peptide. This distinction matters for accurate dosing: if you weigh out 10mg of powder assuming 100% peptide, but net content is 70%, your actual peptide dose is only 7mg.

Disulfide bonds form through oxidative folding after the peptide is cleaved from the resin and deprotected. Cysteine residues are protected during synthesis with trityl (Trt) or acetamidomethyl (Acm) groups to prevent premature oxidation. After cleavage, Trt groups are removed first, and those cysteines are allowed to oxidise in air or dilute iodine, forming the first disulfide bridge. Acm groups are then removed selectively using iodine, and the second disulfide forms. For peptides with multiple disulfide bonds, orthogonal protecting groups allow stepwise, controlled pairing — preventing scrambled disulfides that produce inactive misfolded peptides.

HBTU (O-benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate) and DIC (diisopropylcarbodiimide) are activating reagents that convert the carboxyl group of the incoming amino acid into a reactive intermediate capable of forming a peptide bond with the terminal amine of the growing chain. HBTU is a uronium salt that reacts rapidly and is preferred for difficult couplings, while DIC is a carbodiimide that is more economical and suitable for standard sequences. Both must be stored under anhydrous conditions — hydrolysis of these reagents reduces coupling efficiency and introduces impurities that lower final peptide purity.

Standard custom peptide synthesis (15–30 residues, ≥95% purity) typically takes 2–4 weeks from sequence submission to delivery. This includes synthesis time (1–3 days depending on sequence length), cleavage and crude purification (1–2 days), HPLC purification and lyophilisation (3–5 days), analytical verification via HPLC and mass spectrometry (1–2 days), and quality control review before release. Difficult sequences requiring synthesis optimisation, multiple disulfide bonds, or special modifications can extend timelines to 4–6 weeks. Rush synthesis is available for an additional fee but depends on current production queue and sequence complexity.

Repeated freeze-thaw cycles cause peptide aggregation, precipitation, and loss of bioactivity due to ice crystal formation that disrupts hydrogen bonding and tertiary structure. Each freeze-thaw cycle can reduce activity by 10–20%, and after 5–6 cycles, many peptides lose 50% or more of their original potency. The solution is to aliquot reconstituted peptides into single-use vials immediately after reconstitution — each aliquot is frozen once, thawed once, and used completely. Aliquots stored at −80°C remain stable for months; those kept at 4°C degrade within 1–4 weeks depending on sequence and buffer composition.